Dividends & Buybacks ·
Enlivex shareholders to vote on proposed 1-for-16 reverse stock split to meet Nasdaq $1.00 minimum bid price requirement
ENLVEnlivex Ltd.
Enlivex Ltd. announced an Extraordinary General Meeting of Shareholders scheduled for October 14, 2026, to vote on a proposed reverse stock split of its ordinary shares at a ratio of 1-for-16. The company states the primary purpose is to increase the market price of its shares to satisfy Nasdaq’s continued listing requirement of maintaining a minimum bid price of $1.00 per share, as the shares have closed below this threshold for each trading day from September 10, 2026, through the filing date. If approved, the split will be effective as soon as possible following shareholder approval, and the company’s Articles of Association will be amended accordingly. The record date for voting is October 5, 2026. Enlivex Ltd. operates in the biotechnology industry, focusing on the development of cancer immunotherapies.